Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Boehringer Ingelheim
McKinsey
Mallinckrodt
Merck

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR SYMLIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Symlin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00189514 ↗ A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects Completed AstraZeneca Phase 2 2005-09-01 This is a long term extension to study 137OB-201 which is designed to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
NCT00229658 ↗ An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Completed AstraZeneca 2005-09-01 This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.
NCT00240253 ↗ A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes Completed AstraZeneca Phase 4 2005-10-01 The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.
NCT00313183 ↗ A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus Completed AstraZeneca Phase 2 2006-04-01 This study will be the first evaluation of Symlin in adolescent subjects with type 1 diabetes mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and physiological effects (pharmacodynamics), and safety and tolerability of Symlin in these subjects.
NCT00402077 ↗ A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects Completed AstraZeneca Phase 2 2006-11-01 This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
NCT00467649 ↗ A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes Completed AstraZeneca Phase 4 2007-05-01 This will be a randomized, open label, parallel group, multicenter study. There will be two phases in the study. Phase 1 (Baseline to Week 24) will compare the efficacy and safety of regimens of basal insulin intensified with either Symlin or rapid acting insulin in patients with type 2 diabetes who have either been on a prior regimen of insulin for less than 6 months and were taking less than 50 U total of insulin per day OR are candidates for the initiation of insulin therapy. The purpose of Phase 2 (Week 24 to Week 36) is to explore further intensification of diabetes regimens in patients failing to achieve HbA1c <=6.5% at Week 24.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Symlin

Condition Name

Condition Name for Symlin
Intervention Trials
Type 1 Diabetes 4
Type 2 Diabetes Mellitus 4
Obesity 3
Type 1 Diabetes Mellitus 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Symlin
Intervention Trials
Diabetes Mellitus 11
Diabetes Mellitus, Type 1 8
Diabetes Mellitus, Type 2 6
Body Weight 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Symlin

Trials by Country

Trials by Country for Symlin
Location Trials
United States 152
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Symlin
Location Trials
New York 9
Texas 8
Colorado 7
Florida 7
Pennsylvania 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Symlin

Clinical Trial Phase

Clinical Trial Phase for Symlin
Clinical Trial Phase Trials
Phase 4 8
Phase 3 1
Phase 2 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Symlin
Clinical Trial Phase Trials
Completed 13
Withdrawn 3
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Symlin

Sponsor Name

Sponsor Name for Symlin
Sponsor Trials
AstraZeneca 7
Amylin Pharmaceuticals, LLC. 5
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Symlin
Sponsor Trials
Other 16
Industry 14
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Baxter
Colorcon
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.